Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Cash & Equivalents (2023 - 2025)

Camp4 Therapeutics' Cash & Equivalents history spans 3 years, with the latest figure at $109.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 71.02% year-over-year to $109.5 million; the TTM value through Dec 2025 reached $109.5 million, up 71.02%, while the annual FY2025 figure was $109.5 million, 71.02% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $109.5 million at Camp4 Therapeutics, up from $75.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $109.5 million in Q4 2025 and bottomed at $2.5 million in Q3 2024.
  • The 3-year median for Cash & Equivalents is $49.9 million (2023), against an average of $53.6 million.
  • The largest annual shift saw Cash & Equivalents tumbled 94.99% in 2024 before it surged 2878.64% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $38.4 million in 2023, then soared by 66.86% to $64.0 million in 2024, then surged by 71.02% to $109.5 million in 2025.
  • Per Business Quant, the three most recent readings for CAMP's Cash & Equivalents are $109.5 million (Q4 2025), $75.3 million (Q3 2025), and $39.1 million (Q2 2025).